Clinical Oncology Letters
https://clinicaloncologyletters.com/article/doi/10.4322/col.2019.001
Clinical Oncology Letters
Artigo Original

USO DE FITOTERÁPICOS EM PACIENTES COM CÂNCER NA REGIÃO DO GRANDE ABC

USE OF PHYTOTHERAPY IN CANCER PATIENTS

Camila Ribeiro de Arruda Monteiro, Jean Henri Maselli Schoueri, Karine Corcione Turke, Nicolas Augusto Cabral Ribeiro, Igor Luiz Argani, In Young Noh, Guilherme Querido de Queiroz Ferreira Borrelli, Elaine Shizue Novalo-Goto, Giovanna Cardella Vizentini, João Vitor Maroneze Porfirio, Claudia Vaz de Melo Sette, Daniel de Iracema Gomes Cubero, Auro del Giglio

Downloads: 9
Views: 933

Resumo

Objetivo: Analisar a prevalência do uso dos principais fitoterápicos pela uma população oncológica brasileira atendida pelo Sistema Único de Saúde (SUS), bem como suas indicações e avaliar se houve ou não comunicação à equipe médica do uso dessas substâncias. Métodos: Estudo transversal realizado no serviço de Oncologia da Faculdade de Medicina do ABC com uma amostragem por conveniência. A pesquisa baseou-se na aplicação de questionários a pacientes oncológicos. Resultados: 160 pacientes foram incluídos, dos quais 77 (48,12%) referiram fazer uso de fitoterápicos. Ao analisar o uso ou não de fitoterápicos, foi observada frequência significativamente maior de uso de fitoterápicos em pacientes casados ou amasiados (p=0,001), menor escolaridade (p=0,047) e procedência do ABC (p=0,011). Não foi observada diferença estatisticamente significante quanto ao sexo, raça, ocupação, naturalidade e religião. Não houve, também, direcionamento do uso de um determinado fitoterápico para algum tipo de câncer específico. 21 (27,27%) pacientes revelaram a seus respectivos médicos estar sob uso dessas substâncias, e 33 (42,28%) referiram melhora dos sintomas. Conclusão: O consumo de fitoterápicos foi frequente na população oncológica estudada, sendo esse uso subnotificado para os médicos responsáveis pelo paciente. Considerando os riscos de interações medicamentosas entre fitoterápicos e o tratamento oncológico convencional, é necessário que se questione a pacientes diretamente quanto ao uso de fitoterápicos.

Palavras-chave

Fitoterapia, Oncologia

Abstract

Objective: To analyze the prevalence of the use of phytotherapy by a Brazilian cancer population attended by the Unified Health System (SUS), as well as their indications and to evaluate whether or not there was communication to the medical team about the use of these substances. Methods: Cross-sectional study conducted at the Oncology Department of ABC Medical School with a convenience sampling. The research was based on the application of questionnaires to cancer patients. Results: 160 patients were included, of which 77 (48.12%) reported using herbal medicines. When analyzing the use of herbal medicines, it was observed a significantly higher frequency of herbal medicines use in married or divorced patients (p = 0.001), lower education (p = 0.047) and patients living in ABC cities (p = 0.011). No statistically significant difference was observed regarding gender, race, occupation, place of birth and religion. There was also no direct use of a particular herbal medicine for any specific cancer. 21 (27.27%) patients reported to their respective physicians that they were using these substances, and 33 (42.28%) reported symptom improvement. Conclusion: The use of herbal medicines was frequent in the studied cancer population, and this use was underreported to the doctors responsible for the patient. Considering the risks of drug interactions between herbal medicines and conventional cancer treatment, it is necessary to ask patients directly about the use of herbal medicines.

Keywords

Phytotherapy, Medical concology

Referências

1. Elias MC, Alves E. Medicina não-convencional: prevalência em pacientes oncológicos. Rev Bras Cancerol. 2002;48(4):523-32.

2. Fukumasu H, Latorre AO, Bracci N, Górniak SL, Dagli MLZ. Fitoterápicos e potenciais interações medicamentosas na terapia do câncer. Revista Brasileira de Toxicologia. 2008;21(2):49-59.

3. Brasil. Agência Nacional de Vigilância Sanitária. Resolução de Diretoria Colegiada (RDC) nº 48, de 16 de março de 2004. Dispõe sobre o registro de medicamentos fitoterápicos. Diário Oficial da União [Internet]; Brasília; 18 mar 2012 [citado 2015 nov 8]. Disponível em: http://www.anvisa.gov.br/medicamentos/fitoterapicos/orientacao_RDC48.pdf

4. Carvalho ACB, Balbino EE, Maciel A, Perfeito JPS. Situação do registro de medicamentos fitoterápicos no Brasil. Rev Bras Farmacogn. 2008;18(2):314-9. http://dx.doi.org/10.1590/S0102-695X2008000200028.

5. Damery S, Gratus C, Grieve R, et al. The use of herbal medicines by people with cancer: a cross-sectional survey. Br J Cancer. 2011;104(6):927-33. http://dx.doi.org/10.1038/bjc.2011.47. PMid:21364591.

6. Ali N, Hussain-Gambles M. Complementary and alternative medicine (CAM) use among South Asian patients with cancer in Britain. Diversity Health Social Care. 2005;2(1):41-5.

7. Vickers KA, Jolly KB, Greenfield SM. Herbal medicine: women’s views, knowledge and interaction with doctors: a qualitative study. BMC Complement Altern Med. 2006;6(1):40. http://dx.doi.org/10.1186/1472-6882-6-40. PMid:17156416.

8. Verhoef MJ, Hilsden RJ, O’Beirne M. Complementary therapies and cancer care: an overview. Patient Educ Couns. 1999;38(2):93-100. http://dx.doi.org/10.1016/S0738-3991(99)00056-7. PMid:14528701.

9. Ernst E, Cassileth BR. The prevalence of complementary/alternative medicine in cancer: a systematic review. Cancer. 1998;83(4):777-82. http://dx.doi.org/10.1002/(SICI)1097-0142(19980815)83:4<777::AID-CNCR22>3.0.CO;2-O. PMid:9708945.

10. Meijerman I, Beijnen JH, Schellens JH. Herb-drug interactions in oncology: focus on mechanisms of induction. Oncologist. 2006;11(7):742-52. http://dx.doi.org/10.1634/theoncologist.11-7-742. PMid:16880233.

11. Johns Hopkins Medical Institutions. The role of alternative treatments for cancer. Johns Hopkins Med Lett Health After 50. 2000;11(12):6-7. PMid:10732503.

12. Burstein HJ. Discussing complementary therapies with cancer patients: what should we be talking about? J Clin Oncol. 2000;18(13):2501-4. http://dx.doi.org/10.1200/JCO.2000.18.13.2501. PMid:10893279.

13. Leal F, Schwartsmann G, Lucas HS. Medicina complementar e alternativa: uma prática comum entre os pacientes com câncer. Rev Assoc. Bras. 2008;54(6):481-2. http://dx.doi.org/10.1590/S0104-42302008000600007.

14. Gratus C, Damery S, Wilson S, et al. The use of herbal medicines by people with cancer in the UK: a systematic review of the literature. Q J Med. 2009;102(12):831-42. http://dx.doi.org/10.1093/qjmed/hcp137. PMid:19797394.

15. Schwartsmann G. Developing anticancer agents from natural sources. Clin Adv Hematol Oncol. 2006;5(5):359-61. PMid:16830424.

16. Harris P, Finlay IG, Cook A, Thomas KJ, Hood K. Complementary and alternative medicine use by patients with cancer in Wales: a cross-sectional survey. Complement Ther Med. 2003;11(4):249-53. http://dx.doi.org/10.1016/S0965-2299(03)00126-2. PMid:15022659.

17. Chao MT, Wade CM. Socioeconomic Factors and Women’s Use of Complementary and Alternative Medicine in Four Racial/Ethnic Groups. Ethn Dis. 2008;18(1):65-71. PMid:18447102.

18. Elmer GW, Lafferty WE, Tyree PT, Lind BK. Potential Interactions between complementary/alternative products and conventional medicines in a medicare population. Ann Pharmacother. 2007;41(10):1617-24. http://dx.doi.org/10.1345/aph.1K221. PMid:17785609.

19. Yap KY, See CS, Chan A. Clinically-relevant chemotherapy interactions with complementary and alternative medicines in patients with cancer. Recent Pat Food Nutr Agric. 2010;2(1):12-55. http://dx.doi.org/10.2174/2212798411002010012. PMid:20653549.

20. Ge J, Fishman J, Vapiwala N, et al. Patient-physician communication about complementary and alternative medicine in a radiation oncology setting. Int J Radiat Oncol Biol Phys. 2013;85(1):e1-6. http://dx.doi.org/10.1016/j.ijrobp.2012.08.018. PMid:23040545.

21. Yin S-Y, Wei W-C, Jian F-Y, Yang N-S. Therapeutic applications of herbal medicines for cancer patients. Evid Based Complement Alternat Med. 2013;2013:302426. http://dx.doi.org/10.1155/2013/302426

22. Gerber B, Scholz C, Reimer T, Briese V, Janni W. Complementary and alternative therapeutic approaches in patients with early breast cancer: a systematic review. Breast Cancer Res Treat. 2006;95(3):199-209. http://dx.doi.org/10.1007/s10549-005-9005-y. PMid:16254687.

23. Harlan WR Jr. Research on complementary and alternative medicine using randomized controlled trials. J Altern Complement Med. 2001;7(Suppl 1):45-52. http://dx.doi.org/10.1089/107555301753393805. PMid:11822635.

5f108e860e8825c3075a5963 col Articles
Links & Downloads

Clin Onc Let

Share this page
Page Sections